JP5749161B2 - 抗体産生非ヒト哺乳動物 - Google Patents

抗体産生非ヒト哺乳動物 Download PDF

Info

Publication number
JP5749161B2
JP5749161B2 JP2011516168A JP2011516168A JP5749161B2 JP 5749161 B2 JP5749161 B2 JP 5749161B2 JP 2011516168 A JP2011516168 A JP 2011516168A JP 2011516168 A JP2011516168 A JP 2011516168A JP 5749161 B2 JP5749161 B2 JP 5749161B2
Authority
JP
Japan
Prior art keywords
light chain
human
transgenic
antibody
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011516168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525808A (ja
Inventor
エルウィン・ハウトザハー
ルイ・ダニエル・ピント
トン・ログテンベルグ
マーク・スロスビー
ロバート・アリエン・クラマー
コルネリス・アドリアン・デ・クライフ
Original Assignee
メルス・ベー・フェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41280336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5749161(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by メルス・ベー・フェー filed Critical メルス・ベー・フェー
Publication of JP2011525808A publication Critical patent/JP2011525808A/ja
Application granted granted Critical
Publication of JP5749161B2 publication Critical patent/JP5749161B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011516168A 2008-06-27 2009-06-29 抗体産生非ヒト哺乳動物 Active JP5749161B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NLPCT/NL2008/050430 2008-06-27
NL2008050430 2008-06-27
PCT/NL2009/050381 WO2009157771A2 (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015097258A Division JP2015156871A (ja) 2008-06-27 2015-05-12 抗体産生非ヒト哺乳動物

Publications (2)

Publication Number Publication Date
JP2011525808A JP2011525808A (ja) 2011-09-29
JP5749161B2 true JP5749161B2 (ja) 2015-07-15

Family

ID=41280336

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2011516168A Active JP5749161B2 (ja) 2008-06-27 2009-06-29 抗体産生非ヒト哺乳動物
JP2015097258A Pending JP2015156871A (ja) 2008-06-27 2015-05-12 抗体産生非ヒト哺乳動物
JP2017078941A Active JP6824807B2 (ja) 2008-06-27 2017-04-12 抗体産生非ヒト哺乳動物
JP2020119962A Active JP7242611B2 (ja) 2008-06-27 2020-07-13 抗体産生非ヒト哺乳動物
JP2022147656A Active JP7439201B2 (ja) 2008-06-27 2022-09-16 抗体産生非ヒト哺乳動物
JP2024020295A Pending JP2024063038A (ja) 2008-06-27 2024-02-14 抗体産生非ヒト哺乳動物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015097258A Pending JP2015156871A (ja) 2008-06-27 2015-05-12 抗体産生非ヒト哺乳動物
JP2017078941A Active JP6824807B2 (ja) 2008-06-27 2017-04-12 抗体産生非ヒト哺乳動物
JP2020119962A Active JP7242611B2 (ja) 2008-06-27 2020-07-13 抗体産生非ヒト哺乳動物
JP2022147656A Active JP7439201B2 (ja) 2008-06-27 2022-09-16 抗体産生非ヒト哺乳動物
JP2024020295A Pending JP2024063038A (ja) 2008-06-27 2024-02-14 抗体産生非ヒト哺乳動物

Country Status (23)

Country Link
EP (7) EP2556747B1 (enExample)
JP (6) JP5749161B2 (enExample)
KR (5) KR102112655B1 (enExample)
CN (3) CN102123582B (enExample)
AU (1) AU2009263082C1 (enExample)
CA (1) CA2729095C (enExample)
CY (2) CY1114830T1 (enExample)
DK (4) DK2556747T3 (enExample)
ES (3) ES2853226T3 (enExample)
FI (1) FI3456192T3 (enExample)
HR (2) HRP20220205T1 (enExample)
HU (1) HUE057994T2 (enExample)
LT (2) LT3456192T (enExample)
MX (1) MX2010014542A (enExample)
NZ (1) NZ590118A (enExample)
PL (2) PL3456190T3 (enExample)
PT (4) PT3456192T (enExample)
RS (2) RS53146B (enExample)
RU (2) RU2559524C2 (enExample)
SG (3) SG10201914027VA (enExample)
SI (2) SI2147594T1 (enExample)
WO (1) WO2009157771A2 (enExample)
ZA (1) ZA201009312B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738701B2 (en) 2003-05-30 2017-08-22 Merus N.V. Method for selecting a single cell expressing a heterogeneous combination of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US10934571B2 (en) 2002-07-18 2021-03-02 Merus N.V. Recombinant production of mixtures of antibodies
US11237165B2 (en) 2008-06-27 2022-02-01 Merus N.V. Antibody producing non-human animals

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
RU2559524C2 (ru) * 2008-06-27 2015-08-10 Мерюс Б.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
AU2013204019B2 (en) * 2010-02-08 2014-02-27 Regeneron Pharmaceuticals, Inc. Common light chain mouse
SMT201900372T1 (it) * 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
KR102004106B1 (ko) 2010-03-31 2019-07-25 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
NZ605966A (en) * 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
RU2612903C2 (ru) 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
HUE068728T2 (hu) * 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
EP3816284A1 (en) * 2011-12-22 2021-05-05 F. Hoffmann-La Roche AG Expression vector for antibody production in eukaryotic cells
PL2809150T3 (pl) * 2012-02-01 2020-04-30 Regeneron Pharmaceuticals, Inc. Humanizowane myszy wykazujące ekspresję łańcuchów ciężkich zawierających domeny VL
GB2500113A (en) 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
AU2013204140B2 (en) * 2012-03-06 2016-01-28 Regeneron Pharmaceuticals, Inc. Common light chain mouse
CA2865644A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP3348140B1 (en) 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
SG11201407644UA (en) * 2012-06-05 2014-12-30 Regeneron Pharma Methods for making fully human bispecific antibodies using a common light chain
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
CN103571872B (zh) * 2012-08-09 2016-11-23 山东国际生物科技园发展有限公司 一种能够表达人抗体的转基因动物的制备方法
US10358492B2 (en) 2012-09-27 2019-07-23 Merus N.V. Bispecific IgG antibodies as T cell engagers
GB201303932D0 (en) 2013-03-05 2013-04-17 Oxitec Ltd Muscle actin promoter
PT3501272T (pt) * 2013-03-13 2023-03-29 Regeneron Pharma Murganhos que expressam um repertório limitado de cadeia leve de imunoglobulina
MX368258B (es) 2013-03-15 2019-09-25 Zymeworks Inc Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos.
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
TR201904342T4 (tr) * 2013-10-15 2019-05-21 Regeneron Pharma Hümani̇ze il-15 hayvanlar
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
SI3110849T1 (sl) 2014-02-28 2021-01-29 Merus N.V. Protitelo, ki veže ERBB-2 in ERBB-3
SG11201607109QA (en) 2014-02-28 2016-09-29 Merus Nv Antibodies that bind egfr and erbb3
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
GB2526867A (en) 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
KR102494557B1 (ko) 2014-09-17 2023-02-02 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EP3345928B1 (en) 2015-07-10 2020-06-24 Merus N.V. Human cd3 binding antibody
KR20180038055A (ko) 2015-08-24 2018-04-13 트리아니, 인코포레이티드 면역글로불린의 강화된 생산
BR112018008068A2 (en) 2015-10-23 2018-11-13 Merus N.V. binding molecules that inhibit cancer growth
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
WO2017136734A1 (en) 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
IL263160B2 (en) 2016-06-03 2024-01-01 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
US11827876B2 (en) 2016-08-12 2023-11-28 Oxitec Ltd. Self-limiting, sex-specific gene and methods of using
CN117510643A (zh) 2016-09-23 2024-02-06 美勒斯公司 调节细胞表达的生物活性的结合分子
EP3601528A4 (en) * 2017-03-20 2021-05-05 Washington University CELLS AND METHODS OF USE AND PRODUCTION OF THEM
WO2018182421A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
CA3058343A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
WO2019009728A1 (en) 2017-07-06 2019-01-10 Merus N.V. ANTIBODIES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL
CN119119284A (zh) 2017-07-06 2024-12-13 美勒斯公司 调节由细胞表达的生物活性的结合分子
IL271832B2 (en) 2017-07-06 2025-07-01 Merus Nv Bispecific anti pd1-anti tim3 antibodies and uses thereof
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
HUE071182T2 (hu) 2017-08-09 2025-08-28 Merus Nv EGFR és CMET kötõ antitestek
EP3717008A1 (en) 2017-12-01 2020-10-07 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
PL3720279T3 (pl) * 2017-12-05 2023-01-16 Regeneron Pharmaceuticals, Inc. Myszy posiadające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny oraz ich zastosowania
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
AR117409A1 (es) 2018-03-29 2021-08-04 Oxitec Ltd Noctuidas autolimitantes
MX2020010267A (es) 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
CA3102441C (en) * 2018-06-08 2023-06-13 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain i
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
CN113366018A (zh) 2018-12-20 2021-09-07 美勒斯公司 用于治疗疾病的CLEC12AxCD3双特异性抗体和方法
US12467062B2 (en) 2018-12-21 2025-11-11 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
PH12021551547A1 (en) * 2018-12-31 2022-08-15 Merus Nv Mixed binding domains
MA54643A (fr) 2018-12-31 2021-11-10 Merus Nv Multimères multivalents tronqués
US11008395B2 (en) 2019-01-22 2021-05-18 Bristol Myers-Squibb Company Antibodies against IL-7R alpha subunit and uses thereof
AU2020221649B2 (en) 2019-02-14 2025-03-27 Merus N.V. Producing compositions comprising two or more antibodies.
CA3130248A1 (en) 2019-02-14 2020-08-20 Merus N.V. Combinations of binding moieties that bind egfr, her2 and her3.
AU2020226445B2 (en) 2019-02-18 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
TWI862565B (zh) * 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
TW202108613A (zh) 2019-05-09 2021-03-01 荷蘭商美勒斯公司 用於多聚化蛋白質及其分離的變異區域
AU2020299569A1 (en) * 2019-07-01 2022-01-20 Trianni, Inc. Transgenic mammals and methods of use
TWI889320B (zh) * 2019-07-05 2025-07-01 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
BR112022001473A2 (pt) 2019-07-30 2022-03-22 Ono Pharmaceutical Co Anticorpo biespecífico
EP3772518A1 (en) 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
JP7536085B2 (ja) 2019-08-19 2024-08-19 メルス ナムローゼ フェンノートシャップ Ｌｇｒ５及びｅｇｆｒに結合する抗体とトポイソメラーゼｉ阻害剤との組合せを用いる癌の治療
GB201912008D0 (en) 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
PH12022551527A1 (en) 2019-12-24 2024-01-29 Merus Nv Tgf-beta-rii binding proteins
CN114945596A (zh) 2020-01-29 2022-08-26 美勒斯公司 用于调节免疫细胞衔接效应的手段和方法
CN116731189A (zh) 2020-04-24 2023-09-12 美勒斯公司 使用结合lgr5及egfr的抗体的癌症治疗
AU2021283564B2 (en) 2020-06-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
JP7714992B2 (ja) * 2020-10-02 2025-07-30 小野薬品工業株式会社 二重特異性抗体を有効成分として含む医薬組成物
EP4263604A1 (en) 2020-12-15 2023-10-25 Merus N.V. Treatment of cancers with an antibody that binds lgr5 and egfr
CN116710486A (zh) 2020-12-16 2023-09-05 美勒斯公司 用于治疗癌症的多特异性抗体
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3202123A1 (en) 2020-12-18 2022-06-23 Alexander Berthold Hendrik Bakker Antibody composition
JP7758739B2 (ja) 2020-12-23 2025-10-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンカー改変型抗体をコードする核酸およびその使用
IL311548A (en) 2021-10-06 2024-05-01 Merus Nv Treatment of cancer treated with an immune checkpoint inhibitor and with high EGFR expression by an antibody that binds at least EGFR
CN118632872A (zh) 2022-01-25 2024-09-10 美勒斯公司 用于治疗癌症的组合疗法
MX2024010923A (es) 2022-03-07 2024-09-11 Merus Nv Tratamiento con un anticuerpo que se une al receptor del factor de crecimiento epidermico (egfr) y al receptor cmet.
JP2025509312A (ja) 2022-03-07 2025-04-11 メルス ナムローゼ フェンノートシャップ ＥＧＦＲ及びｃＭＥＴに結合する抗体を含む併用療法
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
GB202217978D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
EP4637817A1 (en) 2022-12-23 2025-10-29 Merus N.V. Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
KR20250128351A (ko) 2022-12-28 2025-08-27 메뤼스 엔.페. Egfr에 결합하는 항체와 세포독성 약물의 조합을 사용한 암의 치료
WO2025105961A1 (en) 2023-11-17 2025-05-22 Merus N.V. COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4531078A (en) 1983-10-27 1985-07-23 Polaroid Corporation Control circuit for electronic flash
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
CA2124967C (en) * 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JPH08140528A (ja) * 1993-12-03 1996-06-04 Genpharm Internatl Inc 異種抗体を産生することができるトランスジェニック非ヒト動物
US5885827A (en) * 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
EP0979281B1 (en) * 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
CA2325721A1 (en) * 1998-03-30 1999-10-07 Research Development Foundation Corticotropin releasing factor receptor 1-deficient mice
US20020028488A1 (en) 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60227067D1 (de) * 2001-05-11 2008-07-24 Kirin Pharma Kk Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
EP1439234A1 (en) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
JP4487068B2 (ja) * 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
WO2006117699A2 (en) 2005-04-29 2006-11-09 Innate Pharma Transgenic animals and methods of making recombinant antibodies
EP2505058A1 (en) * 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
WO2008054606A2 (en) 2006-10-02 2008-05-08 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
RU2559524C2 (ru) * 2008-06-27 2015-08-10 Мерюс Б.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
SMT201900372T1 (it) * 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US10934571B2 (en) 2002-07-18 2021-03-02 Merus N.V. Recombinant production of mixtures of antibodies
US9738701B2 (en) 2003-05-30 2017-08-22 Merus N.V. Method for selecting a single cell expressing a heterogeneous combination of antibodies
US10605808B2 (en) 2003-05-30 2020-03-31 Merus N.V. Antibody producing non-human animals
US10670599B2 (en) 2003-05-30 2020-06-02 Merus N.V. Method for selecting a single cell expressing a heterogeneous combination of antibodies
US11237165B2 (en) 2008-06-27 2022-02-01 Merus N.V. Antibody producing non-human animals

Also Published As

Publication number Publication date
RU2731084C2 (ru) 2020-08-28
EP2147594B1 (en) 2013-11-13
CY1125119T1 (el) 2023-06-09
FI3456192T3 (fi) 2025-12-03
WO2009157771A2 (en) 2009-12-30
EP3456192B1 (en) 2025-09-03
PT2556747T (pt) 2021-02-15
RS53146B (sr) 2014-06-30
PT2147594E (pt) 2014-02-17
CN102123582B (zh) 2015-09-30
CA2729095C (en) 2018-12-04
DK2147594T3 (da) 2014-02-10
HK1154463A1 (zh) 2012-04-27
CN102123582A (zh) 2011-07-13
EP3456192A1 (en) 2019-03-20
ES2906344T3 (es) 2022-04-18
PT3456190T (pt) 2022-02-15
PT3456192T (pt) 2025-11-19
AU2009263082C1 (en) 2018-11-01
RU2015119670A (ru) 2015-12-10
AU2009263082A1 (en) 2009-12-30
MX2010014542A (es) 2011-04-05
JP6824807B2 (ja) 2021-02-03
EP2556747A3 (en) 2016-08-03
JP2017121256A (ja) 2017-07-13
WO2009157771A3 (en) 2010-02-18
JP2011525808A (ja) 2011-09-29
LT3456190T (lt) 2022-03-10
KR20110029156A (ko) 2011-03-22
KR102306491B1 (ko) 2021-09-29
KR20170066688A (ko) 2017-06-14
KR20140127914A (ko) 2014-11-04
CN105191863A (zh) 2015-12-30
JP2015156871A (ja) 2015-09-03
AU2009263082B9 (en) 2014-07-17
SG10201914019YA (en) 2020-03-30
KR101990228B1 (ko) 2019-06-17
KR102112655B1 (ko) 2020-05-19
ZA201009312B (en) 2011-08-31
DK3456192T3 (da) 2025-11-24
EP2147594A1 (en) 2010-01-27
JP2024063038A (ja) 2024-05-10
AU2009263082B2 (en) 2014-03-20
KR20200057093A (ko) 2020-05-25
LT3456192T (lt) 2025-12-10
SG10201408500RA (en) 2015-01-29
CN112481300A (zh) 2021-03-12
EP3456191A1 (en) 2019-03-20
PL2147594T3 (pl) 2014-04-30
EP2556747A2 (en) 2013-02-13
EP3456190A1 (en) 2019-03-20
NZ590118A (en) 2012-10-26
CA2729095A1 (en) 2009-12-30
RU2015119670A3 (enExample) 2019-01-22
RU2020127564A (ru) 2022-02-21
RU2020127564A3 (enExample) 2022-02-21
EP3456193A1 (en) 2019-03-20
KR102261586B1 (ko) 2021-06-08
HRP20220205T1 (hr) 2022-05-27
JP2022188085A (ja) 2022-12-20
EP4650441A2 (en) 2025-11-19
EP2556747B1 (en) 2020-12-02
JP2020191882A (ja) 2020-12-03
HRP20140139T1 (hr) 2014-03-14
CY1114830T1 (el) 2016-12-14
SG10201914027VA (en) 2020-03-30
DK2556747T3 (da) 2021-02-15
JP7439201B2 (ja) 2024-02-27
KR20190025068A (ko) 2019-03-08
CN105191863B (zh) 2020-12-22
RS62925B1 (sr) 2022-03-31
ES2853226T3 (es) 2021-09-15
DK3456190T3 (da) 2022-02-14
ES2445193T3 (es) 2014-02-28
RU2011102962A (ru) 2012-08-10
SI2147594T1 (sl) 2014-02-28
JP7242611B2 (ja) 2023-03-20
RU2559524C2 (ru) 2015-08-10
EP3456190B1 (en) 2021-11-24
PL3456190T3 (pl) 2022-06-06
HUE057994T2 (hu) 2022-06-28
SI3456190T1 (sl) 2022-06-30

Similar Documents

Publication Publication Date Title
JP7439201B2 (ja) 抗体産生非ヒト哺乳動物
US20240164354A1 (en) Antibody producing non-human animals
RU2820926C2 (ru) Продуцирующие антитела млекопитающие, не являющиеся человеком
AU2017276207B2 (en) Antibody producing non-human mammals
HK40044245A (en) Antibody producing non-human mammals
HK40009909A (en) Antibody producing non-human mammals
HK1154463B (en) Antibody producing non-human mammals

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141023

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150413

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150513

R150 Certificate of patent or registration of utility model

Ref document number: 5749161

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250